shares of Replimune Group Inc (REPL) on
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 67 full-time employees. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The firm is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.